Endonovo Therapeutics Inc (ENDV)
0.0022
0.00 (0.00%)
USD |
OTCM |
May 06, 16:00
Endonovo Therapeutics Enterprise Value: 7.944M for May 3, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 03, 2024 | 7.944M |
| May 02, 2024 | 7.766M |
| May 01, 2024 | 8.014M |
| April 30, 2024 | 7.927M |
| April 29, 2024 | 7.840M |
| April 26, 2024 | 7.990M |
| April 25, 2024 | 7.910M |
| April 24, 2024 | 7.944M |
| April 23, 2024 | 7.944M |
| April 22, 2024 | 7.944M |
| April 19, 2024 | 7.986M |
| April 18, 2024 | 8.060M |
| April 17, 2024 | 7.836M |
| April 16, 2024 | 8.091M |
| April 15, 2024 | 8.091M |
| April 12, 2024 | 7.932M |
| April 11, 2024 | 7.932M |
| April 10, 2024 | 7.900M |
| April 09, 2024 | 8.027M |
| April 08, 2024 | 8.091M |
| April 05, 2024 | 8.091M |
| April 04, 2024 | 8.059M |
| April 03, 2024 | 7.897M |
| April 02, 2024 | 7.740M |
| April 01, 2024 | 7.932M |
| Date | Value |
|---|---|
| March 28, 2024 | 8.059M |
| March 27, 2024 | 7.804M |
| March 26, 2024 | 7.804M |
| March 25, 2024 | 8.059M |
| March 22, 2024 | 8.155M |
| March 21, 2024 | 7.804M |
| March 20, 2024 | 8.011M |
| March 19, 2024 | 8.203M |
| March 18, 2024 | 7.804M |
| March 15, 2024 | 8.187M |
| March 14, 2024 | 7.868M |
| March 13, 2024 | 7.995M |
| March 12, 2024 | 8.474M |
| March 11, 2024 | 8.474M |
| March 08, 2024 | 8.378M |
| March 07, 2024 | 8.419M |
| March 06, 2024 | 8.314M |
| March 05, 2024 | 8.155M |
| March 04, 2024 | 8.123M |
| March 01, 2024 | 8.123M |
| February 29, 2024 | 8.174M |
| February 28, 2024 | 8.174M |
| February 27, 2024 | 8.199M |
| February 26, 2024 | 8.027M |
| February 23, 2024 | 8.228M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
6.573M
Minimum
Dec 09 2020
19.87M
Maximum
Jul 03 2019
9.37M
Average
8.587M
Median
Enterprise Value Benchmarks
| NovaBay Pharmaceuticals Inc | 2.813M |
| Palatin Technologies Inc | 24.56M |
| iBio Inc | 16.80M |
| Theriva Biologics Inc | -13.31M |
| Oragenics Inc | 3.216M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.603M |
| Revenue (Quarterly) | 0.006M |
| Total Expenses (Quarterly) | 0.792M |
| Gross Profit Margin (Quarterly) | 49.57% |
| Profit Margin (Quarterly) | -26.80K% |
| Earnings Yield | 237.2% |
| Normalized Earnings Yield | -79.22 |